Licensing status

Publication and contact information



Euchromatic histone-lysine N-methyltransferase 2
(EHMT2; G9A)

In vitro and mouse studies suggest inhibiting G9A-mediated serine-glycine synthesis could help treat cancer. G9A is overexpressed in multiple human cancers and correlates with disease progression. In mouse xenograft tumor models, G9A overexpression was sufficient to promote tumor growth. In multiple cancer cell lines, shRNA knockdown or small molecule inhibition of G9A decreased H3K9 monomethylation of genes encoding enzymes of the serine-glycine biosynthetic pathway, which lowered enzyme levels and serine-dependent cell proliferation compared with control shRNA or no treatment. Next steps include determining how G9A is targeted to genes encoding enzymes in the serine-glycine pathway and testing G9A inhibitors in preclinical cancer models.

SciBX 7(3); doi:10.1038/scibx.2014.81
Published online Jan. 23, 2014

Unpatented; licensing status not applicable

Ding, J. et al. Cell Metab.;
published online Dec. 3, 2013;
Contact: Han-Fei Ding, Georgia Regents University, Augusta, Ga.